Depression | Jotup

Quantum Electrodynamics and Ibogaine: Enhancing Work Performance

Retrieved on:

Sunday, April 21, 2024

Environment, Performance, Ibogaine, Anxiety, Patient, Depression, Telescope

MIAMI, April 21, 2024 (GLOBE NEWSWIRE) -- Ibogaine By David Dardashti, a leader in the field of ibogaine therapy, is introducing a more effective and efficient way to enhance work performance with the help of quantum electrodynamics.

Key Points:

MIAMI, April 21, 2024 (GLOBE NEWSWIRE) -- Ibogaine By David Dardashti, a leader in the field of ibogaine therapy, is introducing a more effective and efficient way to enhance work performance with the help of quantum electrodynamics.
Ibogaine By David Dardashti is utilizing electromagnetism and quantum electrodynamics to enhance the power of ibogaine treatment for those seeking to increase their work performance.
“The timing of ibogaine treatments can be made even more effective with the help of quantum electrodynamics,” claims Dardashti.
Ibogaine By David Dardashti utilizes electromagnetism, quantum electrodynamics, and astronomical cycles to create an optimized and effective ibogaine treatment experience to increase work productivity.

Ibogaine By David Dardashti Announces New Algorithm For Alcohol Addiction

Retrieved on:

Sunday, April 21, 2024

Substance abuse, Alcoholism, Trauma, Element, Mental health, Cocaine, Collection, Research, Depression, Risk, Pharmaceutical industry

MIAMI, April 21, 2024 (GLOBE NEWSWIRE) -- Ibogaine By David Dardashti, a prominent provider of natural and holistic remedies for substance abuse, has developed a novel algorithm to tackle the escalating issue of alcohol addiction.

Key Points:

MIAMI, April 21, 2024 (GLOBE NEWSWIRE) -- Ibogaine By David Dardashti, a prominent provider of natural and holistic remedies for substance abuse, has developed a novel algorithm to tackle the escalating issue of alcohol addiction.
The most crucial element of the addiction treatment algorithm is to ascertain if the individual has attained a stage of physical reliance.
"Our goal is to bring about a significant change in the lives of those battling alcohol dependency," stated David Dardashti, the creator of Ibogaine By David Dardashti.
This algorithm is a product of extensive research and trials conducted over several years by the committed team of scientists at Ibogaine By David Dardashti.

Ibogaine By David Dardashti Introduces New Algorithm for Depression Treatment

Retrieved on:

Sunday, April 21, 2024

Trauma, Patient, Mental health, Research, Depression, Pharmaceutical industry

David Dardashti's Ibogaine has been leading this research, examining the impact of Ibogaine on individuals battling depression.

Key Points:

David Dardashti's Ibogaine has been leading this research, examining the impact of Ibogaine on individuals battling depression.
After extensive research and clinical scrutiny, David Dardashti has formulated a novel algorithm for depression treatment.
This depression treatment algorithm acknowledges the multifaceted nature of the disorder, understanding that it is often shaped by both biological and environmental elements.
The treatment regimen implemented by Ibogaine, as formulated by David Dardashti, is intended to generate Noribogaine in the days succeeding the initial treatment.

PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine

Retrieved on:

Thursday, April 18, 2024

Pain, FDA, Hospital, Food, Health Canada, Depression, Quality, Suicidal ideation, Ketamine, Anesthesia, Mental health, Symantec Endpoint Protection, DSM-IV codes, CRL, Anxiety, Letter, Pharmaceutical industry

Ketamine has been on the FDA’s drug shortage list since February 2018, which is believed to have encouraged the widespread availability of compounded ketamine products not FDA approved for psychiatric disorders.

Key Points:

Ketamine has been on the FDA’s drug shortage list since February 2018, which is believed to have encouraged the widespread availability of compounded ketamine products not FDA approved for psychiatric disorders.
Ketamine is an essential medicine used for anesthesia and analgesia (pain relief) listed on the WHO Essential Medicines List .
In Canada, ketamine has been classified as a Tier 3 drug shortage since February 2023, and Health Canada has approved ketamine for use as a sedative and painkiller in hospital settings.
A recently published new peer-reviewed study on the real-world effectiveness of ketamine intravenous therapy demonstrated significant patient improvement for depression, anxiety and suicidal ideation.

Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor

Retrieved on:

Wednesday, April 17, 2024

Myriad Genetics, MYGN, Depression, Life, Genetic testing, Mental health, Patient, Medicine, Anxiety, Nursing

When able to attend important events, 71% of the respondents say their mental health has kept them from being fully present. Nearly eight in 10 respondents (78%) said poor mental health prevented them from “having fun/enjoying myself” in the past year -- a number that jumps to 82% for those diagnosed with anxiety and/or depression.

Key Points:

SALT LAKE CITY, April 17, 2024 (GLOBE NEWSWIRE) -- An astonishing 44% of Americans feel they have lost time in their lives due to poor mental health.
Of those diagnosed with anxiety and/or depression, half (50%) said they have lost years of their lifetime because of poor mental health – and 12% said they’ve lost decades.
When able to attend important events, 71% of the respondents say their mental health has kept them from being fully present.
“I had to call off my wedding to focus on my mental health,” said Courtney Nugent, a GeneSight patient based in Massachusetts.

PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine

Retrieved on:

Tuesday, April 16, 2024

Pain, FDA, Hospital, Food, Health Canada, Depression, Quality, Suicidal ideation, Ketamine, Anesthesia, Mental health, Symantec Endpoint Protection, DSM-IV codes, Anxiety, Pharmaceutical industry

TORONTO, April 16, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, provides an update of its Priority Original Abbreviated New Drug Application (“ANDA”) for Ketamine that was accepted by the U.S. Food and Drug Administration (the “FDA”) and assigned a Generic Drug User Fee Amendments of 2022 (“GDUFA”) goal date of April 29, 2024.

Key Points:

TORONTO, April 16, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, provides an update of its Priority Original Abbreviated New Drug Application (“ANDA”) for Ketamine that was accepted by the U.S. Food and Drug Administration (the “FDA”) and assigned a Generic Drug User Fee Amendments of 2022 (“GDUFA”) goal date of April 29, 2024.
The Company is prepared to address potential FDA requests and concerns immediately and will update shareholders as they occur.
Ketamine has been on the FDA’s drug shortage list since February 2018, which is believed to have encouraged the widespread availability of compounded ketamine products not FDA approved for psychiatric disorders.
A recently published new peer-reviewed study on the real-world effectiveness of ketamine intravenous therapy demonstrated significant patient improvement for depression, anxiety and suicidal ideation.

Crisis Text Line’s Fifth Annual United in Empathy Report Reveals a Year of Increased Anxiety and Stress

Retrieved on:

Tuesday, April 16, 2024

Volunteering, Video, African, Loneliness, Spouse, Social media, Sadness, Risk, Self-harm, Parent, Bullying, Depression, Suicide, Friends, White, Family, Mental health, Work, Music, Anxiety, Crisis, Sibling, Nursing

Crisis Text Line analyzed 1.3 million anonymized conversations with people in crisis – the majority under the age of 25 – to uncover the top mental health issues, stressors and coping strategies.

Key Points:

Crisis Text Line analyzed 1.3 million anonymized conversations with people in crisis – the majority under the age of 25 – to uncover the top mental health issues, stressors and coping strategies.
In 2023, anxiety and stress was the most prominent topic of Crisis Text Line conversations as over 1 in 3 texters discussed it.
Anxiety and stress were followed closely by relationships (34%); depression and sadness (30%); suicide (18%); and isolation and loneliness (17%).
Individuals who are looking to save and change lives are welcome to join Crisis Text Line’s community of volunteers .

CVRx announces availability of additional data supporting long-term benefits of Barostim

Retrieved on:

Monday, April 15, 2024

MINNEAPOLIS, Minn., April 15, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today the availability of additional data, including the publication of results of the post-market phase of the BeAT-HF trial in the European Journal of Heart Failure. These data highlight long-term sustained benefits of Barostim in heart failure patients with reduced ejection fraction.

Key Points:

(NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today the availability of additional data, including the publication of results of the post-market phase of the BeAT-HF trial in the European Journal of Heart Failure.
These data highlight long-term sustained benefits of Barostim in heart failure patients with reduced ejection fraction.
CVRx previously announced some of these data as part of expanded labeling granted by FDA on December 23, 2023.
We look forward to the generation of additional evidence about Barostim from the BeAT-HF trial, as well as from real-world experience through our REBALANCE post-market registry and investigator-initiated research,” said Hykes.

The ADHD Expert Consortium Hosts Third Annual Meeting

Retrieved on:

Thursday, May 2, 2024

The ADHD Expert Consortium, a diverse group of professionals advocating for improved ADHD care, held its third annual meeting in Houston, Texas.

Key Points:

The ADHD Expert Consortium, a diverse group of professionals advocating for improved ADHD care, held its third annual meeting in Houston, Texas.
During this year’s in-person meeting, the group objective was to identify discrepancies between the guidelines outlined in medical necessity policies and their day-to-day work with patients.
“Despite increased awareness, understanding, and technological advancements surrounding ADHD, the diagnostic process has remained unchanged for decades.
To support these efforts and bring a wealth of expertise in the policy and payor space, the ADHD Expert Consortium added Dori Martini as its newest member.

Relief Mental Health Sheds Light on Innovative Treatments During Mental Health Awareness Month

Retrieved on:

Wednesday, May 1, 2024

As Mental Health Awareness Month kicks off today, Relief Mental Health aims to spotlight innovative therapies that offer hope to individuals struggling with mental health diagnoses.

Key Points:

As Mental Health Awareness Month kicks off today, Relief Mental Health aims to spotlight innovative therapies that offer hope to individuals struggling with mental health diagnoses.
"TMS, Spravato, and IV ketamine represent a new frontier in mental health treatment, offering relief to those who have struggled with traditional therapies,” said Teresa Poprawski, MD , a neuropsychiatrist and chief medical officer at Relief Mental Health.
In honor of Mental Health Month and to help educate the public on the benefits of TMS specifically, Relief Mental Health is hosting an Instagram Live event on Friday, May 17, at 10 a.m. central time.
For more information about Relief Mental Health or to schedule a consultation for any of its services, individuals can call 855.205.4764, email [email protected] or visit reliefmh.com .